Author： Garajová Ingrid Ferracin Manuela Porcellini Elisa Palloni Andrea Abbati Francesca Biasco Guido Brandi Giovanni
Publisher： MDPI
E-ISSN： 1422-0067|18|7|1547-1547
ISSN： 1422-0067
Source： International Journal of Molecular Sciences, Vol.18, Iss.7, 2017-07, pp. : 1547-1547
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The onset and selection of resistant clones during cancer treatment with chemotherapy or targeted therapy is a major issue in the clinical management of metastatic colorectal cancer patients. It is possible that a more personalized treatment selection, using reliable response-to-therapy predictive biomarkers, could lead to an improvement in the success rate of the proposed therapies. Although the process of biomarker selection and validation could be a long one, requiring solid statistics, large cohorts and multicentric validations, non-coding RNAs (ncRNAs) and in particular microRNAs, proved to be extremely promising in this field. Here we summarize some of the main studies correlating specific ncRNAs with sensitivity/resistance to chemotherapy, anti-VEGF therapy, anti-EGFR therapy and immunotherapy in colorectal cancer (CRC).
Related content
Access to resources
Recommend
By Calore Federica Lovat Francesca Garofalo Michela
International Journal of Molecular Sciences, Vol. 14, Iss. 8, 2013-08 ,pp. :